collection
MENU ▼
Read by QxMD icon Read
search

IBD

shared collection
219 papers 500 to 1000 followers
By Jeff Bank Internal Medicine R2 at the University of Utah
https://www.readbyqxmd.com/read/29460920/long-term-safety-of-in-utero-exposure-to-anti-tnf%C3%AE-drugs-for-the-treatment-of-inflammatory-bowel-disease-results-from-the-multicenter-european-teddy-study
#1
M Chaparro, A Verreth, T Lobaton, E Gravito-Soares, M Julsgaard, E Savarino, F Magro, I Avni Biron, P Lopez-Serrano, M J Casanova, M Gompertz, S Vitor, M Arroyo, D Pugliese, Y Zabana, R Vicente, M Aguas, A Bar-Gil Shitrit, A Gutierrez, G A Doherty, L Fernandez-Salazar, J Martínez Cadilla, J M Huguet, A O'Toole, E Stasi, N Manceñido Marcos, A Villoria, K Karmiris, J F Rahier, C Rodriguez, M Diz-Lois Palomares, G Fiorino, J M Benitez, M Principi, T Naftali, C Taxonera, G Mantzaris, L Sebkova, B Iade, D Lissner, I Ferrer Bradley, A Lopez-San Roman, I Marin-Jimenez, O Merino, M Sierra, M Van Domselaar, F Caprioli, I Guerra, P Peixe, M Piqueras, I Rodriguez-Lago, Y Ber, K van Hoeve, P Torres, M Gravito-Soares, D Rudbeck-Resdal, O Bartolo, A Peixoto, G Martin, A Armuzzi, A Garre, M G Donday, F J Martín de Carpi, J P Gisbert
OBJECTIVES: The long-term safety of exposure to anti-tumor necrosis factor (anti-TNFα) drugs during pregnancy has received little attention. We aimed to compare the relative risk of severe infections in children of mothers with inflammatory bowel disease (IBD) who were exposed to anti-TNFα drugs in utero with that of children who were not exposed to the drugs. METHODS: Retrospective multicenter cohort study. Exposed cohort: children from mothers with IBD receiving anti-TNFα medication (with or without thiopurines) at any time during pregnancy or during the 3 months before conception...
February 20, 2018: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/29454042/when-do-you-start-and-when-do-you-stop-screening-for-colon-cancer-in-inflammatory-bowel-disease
#2
Millie D Long, Bruce E Sands
No abstract text is available yet for this article.
February 14, 2018: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29454043/what-is-the-role-of-the-inflammatory-bowel-disease-panel-in-diagnosis-and-treatment
#3
Millie D Long, Bruce E Sands
No abstract text is available yet for this article.
February 14, 2018: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29453383/hyperbaric-oxygen-therapy-is-well-tolerated-and-effective-for-ulcerative-colitis-patients-hospitalized-for-moderate-severe-flares-a-phase-2a-pilot-multi-center-randomized-double-blind-sham-controlled-trial
#4
Parambir S Dulai, Jay C Buckey, Laura E Raffals, Jason M Swoger, Paul L Claus, Kevin O'Toole, Judy A Ptak, Michael W Gleeson, Christella E Widjaja, John T Chang, Jeffery M Adler, Nihal Patel, Laurie A Skinner, Shawn P Haren, Kimberly Goldby-Reffner, Kimberly D Thompson, Corey A Siegel
BACKGROUND: Hyperbaric oxygen therapy (HBOT) markedly increases tissue oxygen delivery. Case series suggest it may have a potential therapeutic benefit in ulcerative colitis (UC). We investigated the therapeutic potential of HBOT as an adjunct to steroids for UC flares requiring hospitalization. METHODS: The study was terminated early due to poor recruitment with 18 of the planned 70 patients enrolled. UC patients hospitalized for moderate-severe flares (Mayo score ≥6, endoscopic sub-score ≥2) were block randomized to steroids + daily HBOT (n = 10) or steroids + daily sham hyperbaric air (n = 8)...
February 16, 2018: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/29453384/longitudinal-impact-of-ibs-type-symptoms-on-disease-activity-healthcare-utilization-psychological-health-and-quality-of-life-in-inflammatory-bowel-disease
#5
David J Gracie, P John Hamlin, Alexander C Ford
OBJECTIVES: The impact of irritable bowel syndrome (IBS)-type symptoms on the natural history of inflammatory bowel disease (IBD) is uncertain. We aimed to address this in a longitudinal study of secondary care patients. METHODS: Longitudinal disease activity was defined by disease flare, escalation of medical therapy, hospitalization, or intestinal resection. The number of investigations performed and clinics attended determined healthcare utilization. Psychological well-being and quality of life were assessed using validated questionnaires...
February 16, 2018: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/29391271/eicosapentaenoic-acid-reduces-fecal-levels-of-calprotectin-and-prevents-relapse-in-patients-with-ulcerative-colitis
#6
Eleonora Scaioli, Alessandro Sartini, Matteo Bellanova, Massimo Campieri, Davide Festi, Franco Bazzoli, Andrea Belluzzi
BACKGROUND & AIMS: High fecal levels of calprotectin indicate mucosal inflammation and have been shown to predict relapse in patients with ulcerative colitis (UC). Eicosapentaenoic acid (EPA), the major component of n-3 fish oil, has anti-inflammatory properties in patients with chronic inflammatory disorders. We performed a placebo-controlled trial of patients with UC at risk of relapse to determine the ability of the free-fatty acid form of EPA (EPA-FFA) to reduce intestinal inflammation, using fecal level of calprotectin as a marker...
January 29, 2018: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29355520/impact-of-capsule-endoscopy-on-prevention-of-postoperative-recurrence-of-crohn-s-disease
#7
Ze-Min Han, Wei-Guang Qiao, Xiu-Yun Ai, Ai-Min Li, Zhen-Yu Chen, Xi-Cheng Feng, Jie Zhang, Tian-Mo Wan, Zhi-Min Xu, Yang Bai, Ming-Song Li, Si-de Liu, Fa-Chao Zhi
BACKGROUND AND AIMS: Capsule endoscopy (CE) could detect lesions outside the scope of ileocolonoscopy in postoperative patients with Crohn's disease (CD). However, the impact of such findings on patient outcomes remains unknown. This study is intended to evaluate the impact of CE findings on clinical management and outcomes in asymptomatic patients with CD without pharmacological prophylaxis after ileocolonic resection. METHODS: In this retrospective cohort study, 37 patients (group 1) received ileocolonoscopy together with CE within 1 year after surgery, whereas 46 patients (group 2) only received ileocolonoscopy...
January 17, 2018: Gastrointestinal Endoscopy
https://www.readbyqxmd.com/read/29336432/increased-mortality-rates-with-prolonged-corticosteroid-therapy-when-compared-with-antitumor-necrosis-factor-%C3%AE-directed-therapy-for-inflammatory-bowel-disease
#8
James D Lewis, Frank I Scott, Colleen M Brensinger, Jason A Roy, Mark T Osterman, Ronac Mamtani, Meenakshi Bewtra, Lang Chen, Huifeng Yun, Fenglong Xie, Jeffrey R Curtis
OBJECTIVES: Crohn's disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases (IBD) that compromise quality of life and may increase mortality. This study compared the mortality risk with prolonged corticosteroid use vs. antitumor necrosis factor-α (anti-TNF) drugs in IBD. METHODS: A retrospective cohort study was conducted among Medicaid and Medicare beneficiaries from 2001 to 2013 with IBD prescribed either >3,000 mg of prednisone or equivalent within a 12-month period or new initiation of anti-TNF therapy, each treated as time-updating exposures...
January 16, 2018: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/29329905/consensus-recommendations-for-evaluation-interpretation-and%C3%A2-utilization-of-computed-tomography-and-magnetic-resonance-enterography-in-patients-with-small-bowel-crohn-s%C3%A2-disease
#9
David H Bruining, Ellen M Zimmermann, Edward V Loftus, William J Sandborn, Cary G Sauer, Scott A Strong
Computed tomography and magnetic resonance enterography have become routine small bowel imaging tests to evaluate patients with established or suspected Crohn's disease, but the interpretation and use of these imaging modalities can vary widely. A shared understanding of imaging findings, nomenclature, and utilization will improve the utility of these imaging techniques to guide treatment options, as well as assess for treatment response and complications. Representatives from the Society of Abdominal Radiology Crohn's Disease-Focused Panel, the Society of Pediatric Radiology, the American Gastroenterological Association, and other experts, systematically evaluated evidence for imaging findings associated with small bowel Crohn's disease enteric inflammation and established recommendations for the evaluation, interpretation, and use of computed tomography and magnetic resonance enterography in small bowel Crohn's disease...
December 30, 2017: Gastroenterology
https://www.readbyqxmd.com/read/29317770/corticosteroid-sparing-in-inflammatory-bowel-disease-is-more-often-achieved-in-the-immunomodulator-and-biological-era-results-from-the-dutch-population-based-ibdsl-cohort
#10
Steven F G Jeuring, Vince B C Biemans, Tim R A van den Heuvel, Maurice P Zeegers, Wim H Hameeteman, Mariëlle J L Romberg-Camps, Liekele E Oostenbrug, Ad A M Masclee, Daisy M A E Jonkers, Marieke J Pierik
OBJECTIVES: Corticosteroid-free remission is an emerging treatment goal in the management of inflammatory bowel disease (IBD). In the population-based Inflammatory Bowel Disease South Limburg cohort, we studied temporal changes in corticosteroid use and assessed the corticosteroid-sparing effects of immunomodulators and biologicals in real life. METHODS: In total, 2,823 newly diagnosed patients with Crohn's disease (CD) or ulcerative colitis (UC) were included. Corticosteroid exposure and cumulative days of use were compared between patients diagnosed in 1991-1998 (CD: n=316, UC: n=539), 1999-2005 (CD: n=387, UC: n=527), and 2006-2011 (CD: n=459, UC: n=595)...
January 9, 2018: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/29257147/utility-of-magnetic-resonance-enterography-for-small-bowel-endoscopic-healing-in-patients-with-crohn-s-disease
#11
Kento Takenaka, Kazuo Ohtsuka, Yoshio Kitazume, Katsuyoshi Matsuoka, Masakazu Nagahori, Toshimitsu Fujii, Eiko Saito, Maiko Kimura, Tomoyuki Fujioka, Mamoru Watanabe
OBJECTIVES: Small bowel (SB) endoscopic healing has not been well studied in patients with Crohn's disease (CD). This study aims to evaluate the utility of magnetic resonance (MR) enterography (MRE) for SB lesions in comparison with balloon-assisted enteroscopy (BAE) findings. METHODS: In total, 139 patients with CD in clinical-serological remission were prospectively followed after BAE and MRE procedures. We applied a modified version of the Simple Endoscopic Score for CD (SES-CD) for an endoscopic evaluation of the SB, called the Simple Endoscopic Active Score for CD (SES-CDa)...
December 19, 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/29231192/defining-an-optimal-adherence-threshold-for-patients-taking-subcutaneous-anti-tnfs-for-inflammatory-bowel-diseases
#12
Shail M Govani, Mohamed Noureldin, Peter D R Higgins, Michele Heisler, Sameer D Saini, Ryan W Stidham, Jennifer F Waljee, Akbar K Waljee
OBJECTIVES: In patients with inflammatory bowel disease (IBD) using biological therapy, non-adherence leads to anti-drug antibody formation and reduced effectiveness. Little is known about the optimal level of adherence in IBD patients on biologic therapy. We aimed to identify the association between adherence and disease flare and determine an optimal level of adherence. METHODS: We analyzed claims data for IBD patients prescribed adalimumab (ADA) and certolizumab (CZP) from the Truven Health MarketScan Commercial Claims and Encounters database from 2009 to 2013...
December 12, 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/29030607/ccdc88b-is-required-for-pathogenesis-of-inflammatory-bowel-disease
#13
Nassima Fodil, Neda Moradin, Vicki Leung, Jean-Frederic Olivier, Irena Radovanovic, Thiviya Jeyakumar, Manuel Flores Molina, Ashley McFarquhar, Romain Cayrol, Dominique Bozec, Naglaa H Shoukry, Michiaki Kubo, Julia Dimitrieva, Edouard Louis, Emilie Theatre, Stephanie Dahan, Yukihide Momozawa, Michel Georges, Garabet Yeretssian, Philippe Gros
Inflammatory bowel disease (IBD) involves interaction between host genetic factors and environmental triggers. CCDC88B maps within one IBD risk locus on human chromosome 11q13. Here we show that CCDC88B protein increases in the colon during intestinal injury, concomitant with an influx of CCDC88B + lymphoid and myeloid cells. Loss of Ccdc88b protects against DSS-induced colitis, with fewer pathological lesions and reduced intestinal inflammation in Ccdc88b-deficient mice. In a T cell transfer model of colitis, Ccdc88b mutant CD4 + T cells do not induce colitis in immunocompromised hosts...
October 13, 2017: Nature Communications
https://www.readbyqxmd.com/read/28886962/endoscopy-in-inflammatory-bowel-disease-advances-in-disease-management
#14
REVIEW
Elizabeth A Scoville, David A Schwartz
No abstract text is available yet for this article.
December 2017: Gastrointestinal Endoscopy
https://www.readbyqxmd.com/read/28853727/evaluation-of-gastrointestinal-patient-reported-outcomes-measurement-information-system-gi-promis-symptom-scales-in-subjects-with-inflammatory-bowel-diseases
#15
Bharati Kochar, Christopher F Martin, Michael D Kappelman, Brennan M Spiegel, Wenli Chen, Robert S Sandler, Millie D Long
OBJECTIVES: Patient reported outcomes (PROs) are important treatment endpoints in inflammatory bowel diseases (IBD). We evaluated the gastrointestinal (GI) PRO Measurement Information System (PROMIS) in IBD subjects. METHODS: Crohn's and Colitis Foundation of America's Partners is an Internet-based cohort of IBD subjects. Participants complete surveys, including demographics, disease characteristics, PROMIS domains, disease activity (short Crohn's disease activity index or simple clinical colitis activity index) and quality of life (QoL) indices...
January 2018: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/28847751/effects-of-mongersen-ged-0301-on-endoscopic-and-clinical-outcomes-in-patients-with-active-crohn-s-disease
#16
Brian G Feagan, Bruce E Sands, Guillermo Rossiter, Xiaobin Li, Keith Usiskin, Xiaojiang Zhan, Jean-Frédéric Colombel
GED-0301 is an antisense oligodeoxynucleotide with a sequence complementary to the Smad7 mRNA transcript. Smad7 is a negative regulator of transforming growth factor-β, which is increased in the intestinal mucosa of patients with active Crohn's disease (CD). We randomly assigned 63 CD patients to 4-, 8-, or 12-week treatment groups receiving oral GED-0301 (160 mg/day). The primary objective was to determine GED-0301's effect on endoscopic CD measures; secondary objectives included effects on clinical activity...
January 2018: Gastroenterology
https://www.readbyqxmd.com/read/28827067/increased-tryptophan-metabolism-is-associated-with-activity-of-inflammatory-bowel-diseases
#17
Susanna Nikolaus, Berenice Schulte, Natalie Al-Massad, Florian Thieme, Dominik M Schulte, Johannes Bethge, Ateequr Rehman, Florian Tran, Konrad Aden, Robert Häsler, Natalie Moll, Gregor Schütze, Markus J Schwarz, Georg H Waetzig, Philip Rosenstiel, Michael Krawczak, Silke Szymczak, Stefan Schreiber
BACKGROUND & AIMS: Administration of tryptophan and some of its metabolites reduces the severity of colitis in mice, whereas removing tryptophan from the diet increases susceptibility to colitis. Transfer of the intestinal microbiome transfers the colitogenic phenotype from tryptophan starved animals to normally nourished mice. We aimed to systematically evaluate serum levels of tryptophan and its metabolites in patients with inflammatory bowel diseases (IBD), and study their association with clinical and serologic features...
December 2017: Gastroenterology
https://www.readbyqxmd.com/read/28809388/dramatic-increase-in-incidence-of-ulcerative-colitis-and-crohn-s-disease-1988-2011-a-population-based-study-of-french-adolescents
#18
Silvia Ghione, Hélène Sarter, Mathurin Fumery, Laura Armengol-Debeir, Guillaume Savoye, Delphine Ley, Claire Spyckerelle, Benjamin Pariente, Laurent Peyrin-Biroulet, Dominique Turck, Corinne Gower-Rousseau
OBJECTIVES: Few data are available to describe the changes in incidence of pediatric-onset inflammatory bowel disease (IBD). The aim of this study was to describe changes in incidence and phenotypic presentation of pediatric-onset IBD in northern France during a 24-year period. METHODS: Pediatric-onset IBD (<17 years) was issued from a population-based IBD study in France between 1988 and 2011. Age groups and digestive location were defined according to the Paris classification...
August 15, 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/28741616/rural-and-urban-residence-during-early-life-is-associated-with-risk-of-inflammatory-bowel-disease-a-population-based-inception-and-birth-cohort-study
#19
Eric I Benchimol, Gilaad G Kaplan, Anthony R Otley, Geoffrey C Nguyen, Fox E Underwood, Astrid Guttmann, Jennifer L Jones, Beth K Potter, Christina A Catley, Zoann J Nugent, Yunsong Cui, Divine Tanyingoh, Nassim Mojaverian, Alain Bitton, Matthew W Carroll, Jennifer deBruyn, Trevor J B Dummer, Wael El-Matary, Anne M Griffiths, Kevan Jacobson, M Ellen Kuenzig, Desmond Leddin, Lisa M Lix, David R Mack, Sanjay K Murthy, Juan Nicolás Peña Sánchez, Harminder Singh, Laura E Targownik, Maria Vutcovici, Charles N Bernstein
OBJECTIVES: To determine the association between inflammatory bowel disease (IBD) and rural/urban household at the time of diagnosis, or within the first 5 years (y) of life. METHODS: Population-based cohorts of residents of four Canadian provinces were created using health administrative data. Rural/urban status was derived from postal codes based on population density and distance to metropolitan areas. Validated algorithms identified all incident IBD cases from administrative data (Alberta: 1999-2008, Manitoba and Ontario: 1999-2010, and Nova Scotia: 2000-2008)...
September 2017: American Journal of Gastroenterology
https://www.readbyqxmd.com/read/28719595/risk-of-postoperative-complications-among-inflammatory-bowel-disease-patients-treated-preoperatively-with-vedolizumab
#20
Akihiro Yamada, Yuga Komaki, Nayan Patel, Fukiko Komaki, Arthur S Aelvoet, Anthony L Tran, Joel Pekow, Sushila Dalal, Russell D Cohen, Lisa Cannon, Konstantin Umanskiy, Radhika Smith, Roger Hurst, Neil Hyman, David T Rubin, Atsushi Sakuraba
OBJECTIVES: Vedolizumab is increasingly used to treat patients with ulcerative colitis (UC) and Crohn's disease (CD), however, its safety during the perioperative period remains unclear. We compared the 30-day postoperative complications among patients treated preoperatively with vedolizumab, anti-tumor necrosis factor (TNF)-α agents or non-biological therapy. METHODS: The retrospective study cohort was comprised of patients receiving vedolizumab, anti-TNF-α agents or non-biological therapy within 4 weeks of surgery...
September 2017: American Journal of Gastroenterology
label_collection
label_collection
2221
1
2
2017-07-20 19:06:48
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"